Tradestie Institutional Equity Comparison Engine

AKRO vs MTVA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AKRO Overall Edge

AKRO Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AKRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MTVA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro) against MTVA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
AKRO N/M vs MTVA N/M Fwd P/E
Growth & Margin Winner AKRO
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner AKRO
1Y +76.8% vs +32.2% ยท 52W Pos 90% vs 4%
Options & Structure Winner AKRO
UNCLASSIFIED (30th %ile IV) vs UNCLASSIFIED (N/A IV)
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
MTVA NASDAQ
MetaVia Inc. Common Stock
Pharmaceutical Preparations
$1.01
-5.61% 1D
Market Cap $7.2M
1M Return -27.34%
1Y Return +32.2%
Forward P/E N/M
Unified AI Score
48.0 / 100 HOLD
Tech 40.0 Fund 60.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AKRO +76.75% MTVA +32.2% Spread: +1407.28 pp (MTVA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AKRO TTM Op. Margin: 0.0% MTVA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs MTVA. Trailing 12-month operating profitability (AKRO 0.0% vs MTVA 0.0%) and valuation multiples (AKRO N/M vs MTVA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AKRO (5) vs MTVA (0)
Institutional Metric AKRO MTVA Criterion Row Winner
Market Capitalization Scale $4.5B $7.2M Larger Scale AKRO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -34.5% -175.7% Higher ROE AKRO
52-Week Range Position Momentum 90% ($21โ€“$58) 4% ($1โ€“$13) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime 0.90ฮฒ ยท 2% Vol 1.30ฮฒ ยท 166% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 60.0 / 100 (BUY) 48.0 / 100 (HOLD) Higher Composite AKRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AKRO vs MTVA Buy Guide
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MTVA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MTVA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AKRO nor MTVA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.